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Abstract
Introduction: Effective transsphenoidal surgery (TSS) for Cushing`s disease (CD) normalizes cortisol levels and reduces complications of 
hypercortisolism. However, there is evidence of increased cardiovascular morbidity even after successful surgery. Objective. A prospective, 
controlled study on the dynamics of fibrinogen and D-dimer levels with a six-month follow-up after an effective TSS for CD. 
Material and methods: Forty patients with CD and forty healthy age- and sex-matched subjects were included. We assessed ACTH, urinary 
and serum cortisol, and fibrinogen and D-dimer levels before TSS and during follow-up. 
Results: Baseline BMI (P < 0.001), fibrinogen (P = 0.002), and D-dimer (P = 0.001) levels in CD patients were significantly higher than 
those in healthy controls. High fibrinogen levels in the CD group were independent of BMI, and were positively associated with hsCRP 
(rS = 0.61, P < 0.001) and arterial hypertension (P = 0.029). After the six-month follow-up we confirmed a sustained difference between 
the remission group and controls in fibrinogen and D-dimer levels (P = 0.001 and P = 0.017, respectively). 
Conclusions: Despite early biochemical remission of CD the levels of fibrinogen and D-dimer failed to decrease. This probably contrib-
utes to the high risk of thrombotic events and indicates the need for a close follow-up for signs of thromboembolic and cardiovascular 
complications in patients with early CD remission. (Endokrynol Pol 2016; 67 (3): 283–291)
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Streszczenie
Wstęp: Skuteczne leczenie chirurgiczne choroby Cushinga prowadzi do normalizacji stężenia kortyzolu i redukcji powikłań hiperkorty-
zolemii. Istotnym spostrzeżeniem jest jednak fakt utrzymywania się zwiększonego ryzyka związanego z powikłaniami sercowo-naczy-
niowymi, nawet po skutecznym leczeniu operacyjnym. 
Celem pracy była prospektywna ocena zmian stężenia fibrynogenu i D-dimerów w okresie 6 miesięcy po przeprowadzonym leczeniu 
chirurgicznym choroby Cushinga.
Materiał i metody: Do badania włączono 40 pacjentów dobranych pod względem płci i wieku z rozpoznaną chorobą Cushinga i 40 osób 
zdrowych. U badanych wykonano oznaczenia stężeń: ACTH, kortyzolu w moczu i surowicy, fibrynogenu i D-dimerów przed leczeniem 
chirurgicznym i w okresie obserwacji.
Wyniki: Wartości BMI (P < 0,001), fibrynogenu (P = 0,002) i D-dimerów (P = 0,001) były istotnie wyższe w grupie pacjentów z choroba 
Cushinga w porównaniu ze zdrowymi osobami. Wysokie stężenie fibrynogenu wśród pacjentów z chorobą Cushinga było niezależne 
od wartości BMI, ale wykazywało dodatnią zależność od wartości hsCRP (rS = 0,61, P < 0,001) i występowania nadciśnienia tętniczego 
(P = 0,029). Potwierdzono utrzymywanie się istotnej różnicy stężeń fibrynogenu i D-dimerów (P = 0,001 i P = 0,017, odpowiednio) po 
6 miesiącach od operacji pomiędzy chorymi, u których uzyskano remisję hiperkortyzolemii i osobami zdrowymi.
Wnioski: Mimo wczesnej remisji hiperkortyzolemii w chorobie Cushinga, stężenia fibrynogenu i D-dimerów nie ulegają obniżeniu. 
Prawdopodobnie jest to przyczyną wysokiego ryzyka incydentów zakrzepowo-zatorowych u tych chorych, a także wskazanie do ścisłej 
obserwacji pooperacyjnej chorych w okresie remisji. (Endokrynol Pol 2016; 67 (3): 283–291)
Słowa kluczowe: hiperkortyzolemia; kortyzol; choroba Cushinga; fibrynogen, D-dimery; operacja przezklinowa;  
powikłania zakrzepowo-zatorowe
Grzegorz Zieliński M.D., Department of Neurosurgery, Military Institute of Medicine, ul. Szaserów 128, 04–141 Warsaw, Poland,  
e-mail: gzielinski@wim.mil.pl
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Introduction
Cushing’s Disease (CD) is the most common cause of 
ACTH-dependent hypercortisolaemia. Transsphenoidal 
selective adenomectomy (TSS), performed by an expe-
rienced neurosurgeon, remains the treatment of choice. 
CD-related hypercortisolism leads to the development 
of cardiovascular and metabolic complications, which 
increases both cardiovascular morbidity and mortality, 
often lowering quality of life [1–6]. Successful surgical 
treatment results in normalisation of hypothalamic-
pituitary axis parameters, improves clinical signs and 
symptoms, and reduces hypercortisolism-related com-
plications, such as hypertension or diabetes. However, 
elevated cardiovascular risk has been demonstrated to 
persist for up to five years following successful surgi-
cal treatment [7, 8]. This persisting cardiovascular risk 
as well as the estimated 15–20% recurrence rate require 
a long-lasting postoperative follow-up [1–4, 7].
Chronic hypercortisolism, which is the essence of 
CD, as well as the glucocorticoids used in drug therapy 
lead to blood coagulation abnormalities by increas-
ing the incidence of venous thromboembolism and 
accelerating the development of atherosclerosis. The 
hypercoagulable state can lead to increased incidence of 
thromboembolic episodes in the postoperative period or 
during diagnostic procedures such as inferior petrosal 
sinus sampling [9–14]. Boscaro et al. demonstrated 
significantly higher thromboembolic mortality and 
morbidity in a group of Cushing’s syndrome patients 
receiving no anti-thromboembolic prevention in com-
parison with those in a group receiving prophylactic 
treatment with the use of warfarin or heparin [14]. 
There is still a need for prospective, controlled stud-
ies on the role of individual coagulation parameters 
and the changes in their levels following successful 
pituitary surgery for CD. The purpose of this study was 
to prospectively evaluate the levels of fibrinogen and D-
dimers, the changes of these parameters over a period 
of six months (early remission), and their association 
with characteristics specific to CD in a homogeneous 
group of patients following successful transsphenoidal 
corticotropinoma resection.
Material and methods
Patient population
The study population consisted of 40 consecutive 
patients with Cushing’s disease (32 women and 
8 men; F:M ratio: 4:1) hospitalised in the Department 
of Endocrinology and operated on in the Department 
of Neurosurgery of the Military Institute of Medicine in 
Warsaw between 2013 and 2015. The mean age of the 
study group was 42.4 ± 15.7 years (range: 17–79 years). 
After confirmed diagnosis of Cushing`s disease the 
patients were operated on by the same neurosurgeon 
using the same surgical protocol. The control group 
comprised 40 healthy sex- and age-matched volunteers 
at the mean age of 42.9 ± 14.3 years (range: 21–79 years).
All patients were informed about the aims and meth-
ods of the study and they each signed the informed 
consent. The study protocol was approved by the 
Ethics Committee at the Military Institute of Medicine 
in Warsaw. 
Preoperative endocrine  
and coagulation assessment
All patients underwent a standard clinical evaluation 
with an assessment of BMI, any history of hypertension, 
and glucose homeostasis alterations. The diagnosis of 
ACTH-dependent Cushing’s syndrome (CS) was made 
based on the clinical signs and standard hormonal cri-
teria: increased urinary free cortisol (UFC), increased 
morning serum cortisol levels at 8.00, loss of cortisol cir-
cadian rhythm (the serum cortisol level above 7.5 µg/dL 
in the late-night hours (22.00–00:00)), increased or 
detectable plasma ACTH levels at 8.00, and failure 
to suppress serum cortisol levels to less than or equal 
to 1.8 µg/dL during an overnight dexamethasone sup-
pression test (ODST; 1 mg at midnight). The pituitary 
aetiology of CS was confirmed based on serum cortisol 
or UFC suppression greater than 50% with a high-dose 
dexamethasone suppression test (HDDST; 2 mg q.i.d. for 
48 hours) and positive pituitary MRI. In cases of incon-
clusive hormonal assessment and pituitary imaging the 
diagnosis of CD was confirmed by a positive result of 
a stimulation test with intravenous CRH injection (100 µg) 
and/or results of inferior petrosal sinus sampling (IPSS). 
As well as the standard hormonal assessment, all pa-
tients had blood samples taken for testing fibrinogen, 
D-dimer, and hsCRP levels. These blood samples were 
collected in the fasting state from the antecubital vein 
into test tubes with 3.2% sodium citrate (fibrinogen and 
D-dimer) and with clotting activator (hsCRP) between 
07:00 and 08:00 and centrifuged for 15 minutes at 2000 
grams or 10 minutes at 1500 grams, respectively.
Preoperative MRI
Prior to neurosurgical treatment all patients underwent 
high-resolution magnetic resonance imaging of the 
pituitary-hypothalamic region (GE Signa, 1.5 Tesla), 
performed before and after intravenous injection of 
gadolinium (Gd-DTPA). Any hypodense lesion visu-
alised after contrast administration was considered to 
be indicative of pituitary adenoma. Microadenoma 
was defined as a pituitary tumour with a diameter of 
less than 1 cm, whereas macroadenoma was defined as 
a tumour with at least one diameter of more than 1 cm.
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Surgical procedure
A microsurgical transseptal transsphenoidal approach 
was used for resection of an ACTH-secreting pituitary 
adenoma. The pituitary gland was carefully examined, 
regardless of MRI findings. Selective adenomectomy 
was performed in all cases of MRI-visualised pituitary 
adenomas. Where MRI findings were inconclusive or no 
tumour was evident, a series of vertical and horizontal 
incisions of the pituitary gland were performed and all 
tissue that was deemed abnormal was removed and 
submitted for pathological examination. 
Postoperative hormonal evaluation  
and criteria of cure
Blood samples for serum cortisol measurements were 
collected from all patients at 06:00 on the first postop-
erative day. Glucocorticoids were not administered in 
the perioperative or in the early postoperative period. 
Hydrocortisone replacement therapy was started after 
biochemical confirmation of hypercortisolaemia or 
the development of clinical manifestations of adrenal 
insufficiency. The standard dose of hydrocortisone 
(20 mg in the morning and 10 mg at 15.00) was intro-
duced when necessary and continued until the next 
hormonal evaluation. 
Following the surgical procedure, all patients were 
subjected to further postoperative evaluation. Sub-
sequent reassessments of hormonal and coagulation 
parameters were performed at three and six months 
after pituitary surgery. Patients on hydrocortisone 
replacement therapy had their cortisol measurements 
taken 48 hours after the last administered dose. We 
used the following criteria for early remission: clinical 
and biochemical evidence of adrenal insufficiency or, 
in the case of preserved adrenal function, biochemical 
evidence of eucortisolaemia: UFC, morning serum 
cortisol and plasma ACTH levels within their respec-
tive reference ranges, preserved circadian rhythm of 
serum cortisol (the late night serum cortisol level £ 7.5 
µg/dL), and ODST-induced serum cortisol suppression 
to £ 1.8 µg/dL.
Laboratory assays
Human adrenocorticotropic hormone (ACTH) levels 
were assessed using solid-phase, two-site immunora-
diometric assay (IRMA ELSA-ACTH, CIS bio Interna-
tional, France). The analytical sensitivity was 2 pg/mL 
(reference range: 10–60 pg/mL). Serum cortisol concen-
trations were determined by electrochemiluminescence 
immunoassay (ECLIA) (Elecsys 2010, Roche Diagnostics, 
Switzerland). Analytical sensitivity was 0.02 µg/dL 
(reference range in the morning: 6.2–19.4 µg/dL; 
in the afternoon: 2.3–11.9 µg/dL). Urinary cortisol after 
extraction (dichloromethane) was measured by coated-
tube radioimmunoassay (RIA) kits (Cortisol RIA kit, 
Immunotech, Czech Republic). Analytical sensitivity 
was 1.8 µg. The reference range was 13.7–75.3 µg/24 hr. 
D-dimer levels were measured via an automated im-
munoturbidimetric method with polystyrene latex 
beads (HemosIL D-Dimer HS 500). The cut-off point 
was 0.5 µg/mL and method sensitivity was 0.215 µg/mL. 
Fibrinogen levels were measured via Clauss method 
using a Q.F.A. thrombin kit. The reference range was 
200–393 mg/dL. Serum fibrinogen and D-dimer levels 
were measured with an ACL TOP 500 CTS analyser 
(Instrumentation Laboratory, a Werfen Company). Blood 
hsCRP levels were measured by immunonephelometry 
with a BN ProSpec® System analyser (Siemens Health-
care, Germany). The cut-off point was 2.87 mg/L and 
method sensitivity was 0.175 mg/L.
Statistical analysis
Methods of descriptive statistics (mean, median, standard 
deviation, range, interquartile range, proportion) were 
employed in the statistical analysis. The hypotheses 
concerning the relationship between two variables were 
verified using the exact chi-square test (Fisher’s exact 
test) for categorical characteristics and test for Spearman’s 
correlation coefficient (rS) for continuous parameters. The 
significance of the differences between average values 
of continuous variables in two groups was analysed by 
means of the t-Student test for normally distributed data 
and the Mann-Whitney test for non-normally distributed 
data. Multiple linear regression was applied to study the 
relationship between one continuous dependent variable 
and two independent variables. Verification of hypotheses 
concerning comparisons of the continuous parameters in 
two time points was conducted using paired t-Student test 
or the Wilcoxon test depending on assumptions. The level 
of significance was set at P < 0.05. All calculations were 
made using the commercially available statistical software 
package IBM SPSS v. 22.
Results
Preoperative characteristics
Table I presents a comparison of demographic data, 
body mass index (BMI), the levels of fibrinogen, D-
dimers, hsCRP, serum cortisol, and plasma ACTH 
obtained in the preoperative period from 40 patients 
with Cushing’s disease (CD) against the analogous 
parameters obtained from the control group of healthy 
volunteers matched for sex and age.
The CD group was additionally evaluated for 
other routinely assessed hormonal parameters of the 
pituitary-adrenal axis. Median UFC excretion in 24-hour 
urine collection was 285.4 µg/dL (IQR 190.5–450.5), the 
mean midnight serum cortisol level was 17.2 ± 6.6 µg/ 
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/dL, and the median cortisol level following an over-
night dexamethasone suppression test was 12.9 µg/dL 
(IQR 6.6–22.1).
Magnetic resonance imaging (MRI) revealed 
a pituitary microadenoma in 33 patients (83%) and 
a macroadenoma in 7 patients (17%) with CD.
Hypertension, a known complication of hypercor-
tisolism, was diagnosed in 30 patients (75%) from the 
CD group. Glucose metabolism disorders were found 
in 29 patients (72.5%) from the CD group. Diagnostic 
criteria for diabetes were met by 11 patients (27.5%) 
and the criteria for pre-diabetes by 18 patients (45%).
Then, the study group was evaluated for relation-
ships between levels of fibrinogen, D-dimers against de-
mographic, anthropometric, hormonal, and biochemi-
cal parameters. No significant correlation was found 
between fibrinogen levels and the age of CD patients 
(rS = 0.21; P = 0.202). However, there was a positive cor-
relation between D-dimer levels and age in this group 
(rS = 0.34; P = 0.035). Our findings suggested a positive 
correlation between serum fibrinogen levels and BMI in 
the study group (rS = 0.28; P = 0.084). Such a correlation 
was not observed in the case of D-dimers (rS = 0.13; 
P = 0.424). Subsequently, a multivariate linear regres-
sion model was used to analyse the impact of BMI on 
the difference in fibrinogen concentration between 
CD and the control group. This analysis revealed the 
fibrinogen levels to be significantly higher in the CD 
group (b = 43.3; P = 0.023), irrespective of BMI values 
(b = 2.1; P = 0.159). No significant correlation was ob-
served between fibrinogen levels and serum cortisol lev-
els at 08:00 (rS = 0.01; P = 0.973), at midnight (rS = –0.03; 
P = 0.852), following an ODST (rS = 0.10; P = 0.538), or 
UFC levels (rS = –0.25; P = 0.114). Similarly, no correlation 
was demonstrated between D-dimer levels and the above 
hormonal parameters, with the corresponding Spear-
man’s rho values of 0.11 (P = 0.511), –0.03 (P = 0.860), 
–0.16 (P = 0.339), and –0.09 (P = 0.587), respectively. 
However, the tests demonstrated a positive correla-
tion between fibrinogen and hsCRP levels both in 
the CD group (rS = 0.61; P < 0.001) and in the control 
group (rS = 0.56; P < 0.001). The correlation between 
plasma D-dimer levels and serum hsCRP levels in the 
CD group showed borderline statistical significance 
(rS = 0.31; P = 0.054). The mean fibrinogen level in the 
study group was shown to be significantly higher in the 
hypertensive patients than that in the normotensive 
individuals (347.7 vs. 293.8; P = 0.029). However, there 
were no significant differences between mean plasma 
D-dimer levels in the hypertensive and normotensive 
subgroups (0.49 µg/mL vs. 0.43 µg/mL; P = 0.662). The 
diabetic and non-diabetic patient subgroups showed 
no differences in terms of mean fibrinogen levels 
(346.7 mg/dL vs. 329.5 mg/dL; P = 0.515) or median 
D-dimer levels (0.53 µg/mL vs. 0.45 µg/mL; P = 0.820).
Results of surgical treatment  
and perioperative assessment
A total of 40 study patients underwent surgical treatment. 
In 38 cases (95%) it was the first-time surgical treatment, 
while 2 patients (5%) underwent a transsphenoidal sur-
gery for the second time. Six months after surgery, early 
CD remission (based on pre-determined criteria) was con-
firmed in 32 patients (80%), while the remaining 8 patients 
(20%) were diagnosed with persistent hypercortisolism. 
Median nadir serum cortisol on postoperative day 1 was 
1.3 µg/dL (IQR: 0.72–4.45) for the whole study group. In the 
remission and persistent hypercortisolism subgroups the 
median nadir cortisol levels were 0.995 µg/dL and 12.600 
µg/dL, respectively (P < 0.001).
Postoperative assessment  
of the evaluated parameters
Table II shows detailed postoperative results of hormonal 
parameters, fibrinogen, D-dimer levels, as well as BMI 
values in the remission group (n = 32). These parameters 
were evaluated 3 and 6 months after surgery. Addition-
ally, Figure 1 and 2 illustrate the changes in serum cortisol 
Table I. Preoperative characteristics of Cushing disease patients and the control group
Tabela I. Przedoperacyjna charakterystyka pacjentów z chorobą Cushinga i grupy kontrolnej
Cases (n = 40) Controls (n = 40) P-value
Age (years, mean ± SD) 42.4 ± 15.7 42.9 ± 14.3 0.897
Women (%) 80.0% 80.0% 1.000
BMI [kg/m2, mean ± SD] 30.8 ± 6.8 24.2 ± 3.5 < 0.001
Cortisol [µg/dL, median, IQR] 22.2 (17.0–31.5) 12.3 (10.0–17.4) < 0.001
ACTH [pg/mL, median, IQR 73.5 (46.7–96.1) 16.6 (11.0–23.3) < 0.001
D-dimer [µg/mL, median, IQR] 0.485 (0.293–0.873) 0.320 (0.195–0.435) 0.002
Fibrynogen [mg/dL, mean ± SD 334.2 ± 74.3 278.1 ± 65.3 0.001
hsCRP [mg/dL, median, IQR] 0.125 (0.040–0.375) 0.095 (0.040–0.200) 0.668
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Table II. Dynamics of hormonal parameters, BMI, fibrinogen, and D-dimer before (t0), 3 months (t3), and 6 months (t6) after 
surgery in Cushing disease patients in early remission (n = 32)
Tabela II. Zmiany wyników badań hormonalnych, BMI, fibrynogenu, D-dimerów przed (t0), 3 miesiące (t3) i 6 miesięcy (t6) 
po skutecznej operacji przezklinowej z powodu choroby Cushinga (n = 32)
ACTH [pg/mL] 
median (IQR)
Cortisol [µg/dL] 
median (IQR)
UFC [µg/24 h] 
median (IQR)
BMI [kg/m2]  
mean ± SD
Fibrinogen [mg/dL] 
mean ± SD
D-dimer [µg/mL] 
median (IQR)
t0 68.4 (45.1–88.0) 21.6 (16.3–31.4) 294.0 (204.1–461.0) 31.2 ± 7.1 325.4 ± 75.4 0.430 (0.293–0.793
t3 9.7 (7.0–14.5) 1.1 (0.4–4.2) 6.6 (2.2–13.5) 29.6 ± 6.9 327.7 ± 75.6 0.605 (0.450–0.950)
t6 11.3 (8.4–16.4) 2.3 (0.8–6.8) 13.0 (2.8–31.0) 27.9 ± 6.2 343.8 ± 91.6 0.425 (0.263–0.708)
P (t3 vs. t0) < 0.001 < 0.001 < 0.001 < 0.001 0.875 0.056
P (t6 vs. t3) 0.137 0.027 < 0.001 < 0.001 0.203 0.001
P (t6 vs. t0) < 0.001 < 0.001 < 0.001 < 0.001 0.230 0.765
Figure 1. Median concentration of serum cortisol and mean fibrinogen levels after TSS in CD patients in early remission (n = 32)
Rycina 1. Mediana stężenia kortyzolu w surowicy i średnie stężenia fibrynogenu u pacjentów poddanych skutecznej operacji przezklinowej 
z powodu choroby Cushinga (n = 32)
Figure 2. Median concentration of serum cortisol and median plasma D-dimer levels after surgery in Cushing disease patients in early 
remission (n = 32)
Rycina 2. Mediana stężenia kortyzolu w surowicy i mediana stężenia D-dimerów po skutecznej operacji przezklinowej z powodu 
choroby Cushinga (n = 32)
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and plasma fibrinogen levels as well as serum cortisol and 
plasma D-dimer levels in the remission group.
The smaller (n = 8) group of patients with persistent 
hypercortisolaemia (lack of remission) had a median 
preoperative 08:00 serum cortisol level of 23.8 µg/dL 
(range: 12.0–69.7), whereas three and six months after 
surgery the levels were 18.5 µ/dL (range: 11.9–33.8) and 
17.4 µg/dL (range: 13.3–57.6), respectively. The median 
preoperative plasma ACTH level was 108.2 pg/mL 
(range: 46.6–563.0), and three and six months postop-
eratively: 51.3 pg/mL (range: 31.4–215.2) and 46.3 pg/mL 
(range: 5.9–290.1), respectively. The preoperative me-
dian urinary free cortisol in the group with persistent 
hypercortisolism was 258.2 µg/24h (range: 134.4–552.0), 
3 and 6 months after the surgery: 91.3 µg/24h (range: 
57.6–670.8) and 117.4 µg/24h (range: 41.3–815.3), respec-
tively. The mean preoperative fibrinogen level in the 
persistent CD group was 369.5 mg/dL (range: 243–441), 
and three and six months after surgery: 367.8 mg/dL 
(range: 299–443) and 367.4 mg/dL (range: 306–417), 
respectively. The median preoperative D-dimer level in 
the persistent hypercortisolism group was 0.575 µg/mL 
(range: 0.200–0.950), and three and six months after sur-
gery: 0.455 µg/mL (range: 0.260–1.140) and 0.440 µg/mL 
(range: 0.260–1.400), respectively.
Then, plasma fibrinogen and D-dimer levels in the 
CD remission subgroup measured preoperatively, three 
and six months after a successful TSS were compared 
with these parameters in the control group. The mean 
preoperative fibrinogen level in the CD remission group 
and fibrinogen level in the control group were 325.44 ± 
± 75.38 mg/dL vs. 278.1 ± 65.3 mg/dL, respectively 
(P = 0.006). Mean fibrinogen levels in the CD remission 
group three and six months after surgery in comparison 
with the corresponding fibrinogen levels in the control 
group were 327.7 ± 75.6 mg/dL vs. 278.1 ± 65.3 mg/dL 
(P = 0.004) and 343.8 ± 91.5 mg/dL vs. 278.1 ± 65.3 mg/dL 
(P = 0.001), respectively. Similarly, median D-dimer 
levels in the remission group measured before surgery, 
three and six months after transsphenoidal surgery in 
comparison with the control group were 0.430 µg/mL 
(IQR 0.293–0.793) vs. 0.320 µg/mL (IQR 0.195–0.435), 
P = 0.005; 0.605 µg/mL (IQR 0.450–0.950) vs. 0.320 
(IQR 0.195–0.435), P < 0.001; and 0.425 µg/mL (IQR 
0.263–0.708) vs. 0.320 (IQR 0.195–0.435), P = 0.017, 
respectively. Figure 3 and 4 show a comparison of the 
remission group, persistent disease group, the control 
group in terms of fibrinogen, and D-dimer levels at the 
end of six-month follow-up.
Discussion
The rate of symptomatic thromboembolic complications 
following surgical procedures in the general population 
is approximately 1%. However, in the case of major 
high-risk orthopaedic (e.g. total hip replacement), 
neurosurgical, urological procedures the rate is higher 
at 2–3% [15,16]. In a meta-analysis of 15 studies evalu-
ating the effect of endogenous hypercortisolism on 
coagulation and fibrinolysis abnormalities, Van Zaane 
et al. estimated the risk of venous thromboembolism 
(VTE) not provoked by surgery to be 1.9–2.5%, while 
postoperative VTE rates ranged from 0 to 5.6% [10]. 
Manetti et al. reported VTE in 7.5% of patients with 
Cushing’s syndrome, while Boscaro reported VTE in 
up to 4.4% of patients, despite postoperative antithrom-
botic prophylaxis [9, 14]. These results suggest that the 
CD population has a dramatically higher risk of VTE 
episodes than the general population.
Our study was a prospective evaluation of changes 
in fibrinogen (a cardiovascular risk marker and a co-
agulation factor) as well as D-dimer levels (a marker 
of coagulation and fibrinolysis system activation) in 
a homogeneous group of 40 patients with CD before 
pituitary surgery, three and six months after TSS.
Fibrinogen, has been classified as an acute phase 
protein, an established independent risk factor of car-
diovascular and cerebrovascular disease [17, 18]. High 
fibrinogen levels have been observed in patients with 
myocardial infarction, stroke, and transient ischaemic 
attacks, i.e. in conditions characterised by an undeniable 
thrombotic aspect [18–21]. Fibrinogen levels have been 
demonstrated to be higher with age, in smokers, in the 
obese, in diabetes, and in hypertension [18, 19]. Fibrino-
gen is very likely to be a mediator of the prothrombotic 
effect of other cardiovascular risk factors [17, 18, 22]. 
The pathophysiological mechanisms involved in this 
effect include its impact on platelet aggregation and 
vascular endothelial function. Fibrinogen also affects 
the fluidity of blood by increasing blood viscosity and 
platelet aggregation [18–21, 23].
Our study demonstrated significantly higher fi-
brinogen levels in the group of patients with CD in 
comparison with those in the sex- and age-matched 
control group. An increase of fibrinogen levels in CD 
patients had already been reported in the scant litera-
ture on the subject [9, 24]. At the same time, we did not 
demonstrate any correlation between fibrinogen levels 
and patient age, serum cortisol levels, and urinary free 
cortisol levels (UFC), which are the hormonal param-
eters routinely evaluated in laboratory diagnostic tests 
for hypercortisolism. Moreover, we demonstrated no 
association between fibrinogen levels and the rates of 
hypertension or carbohydrate metabolism in the study 
group. 
However, we would like to emphasise the observed 
positive correlation between fibrinogen and hsCRP 
levels. This is consistent with the association between 
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these two acute phase proteins demonstrated in the 
general population, indicating the coexistence of 
inflammation and the state of thrombotic readiness 
also in patients with CD [22, 25, 26]. Thus, finding con-
comitantly elevated fibrinogen and hsCRP levels might 
help identify patients with high cardiovascular risk not 
only in the general population but also among patients 
with CD. This, however, requires further studies with 
a larger number of patients and a longer postoperative 
follow-up period.
The association between fibrinogen levels and 
body mass index (BMI) also seems to be important. 
We demonstrated both significantly higher fibrinogen 
levels and significantly higher BMI values in the group 
of CD patients in comparison with those in the control 
group. These findings are consistent with those by van 
der Pas et al. [11]. However, in our study we confirmed 
in multivariate analysis that the differences in BMI do 
not fully explain the higher fibrinogen levels in CD 
patients comparatively to controls. 
An important finding demonstrated in our study 
was the persistently higher fibrinogen levels through-
out the six months following a successful surgical 
treatment, in comparison with the control group. This 
Figure 4. Concentration of plasma D-dimer 6 months after surgery in Cushing disease patients in early remission (n = 32) and with 
persistent CD (n = 8) in comparison to the control group (n = 40)
Rycina 4. Stężenie D-dimerów po 6 miesiącach od operacji przezklinowej z powodu choroby Cushinga u pacjentów w okresie wczesnej 
remisji (n = 32) i pacjentów z przetrwałą chorobą (n = 8) w porównaniu z grupą kontrolną (n = 40)
Figure 3. Concentration of plasma fibrinogen 6 months after surgery in Cushing disease patients in early remission (n = 32) and with 
persistent CD (n = 8) in comparison to the control group (n = 40)
Rycina 3. Stężenie fibrynogenu po 6 miesiącach od operacji przezklinowej z powodu choroby Cushinga u pacjentów w okresie wczesnej 
remisji (n = 32) i pacjentów z przetrwałą chorobą (n = 8) w porównaniu z grupą kontrolną (n = 40)
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Fibrinogen and D-dimer levels fail to normalise despite early postoperative remission Przemysław Witek et al.
phenomenon occurred despite the achieved normalisa-
tion in terms of hormonal parameters of the pituitary-
adrenal axis. Fibrinogen levels did not only remain 
significantly higher than those in the control group, but 
also remained higher than the baseline preoperative 
levels. The absence of a decrease in fibrinogen levels 
despite significant body mass reduction is another piece 
of evidence that this cardiovascular risk factor and the 
marker of thrombotic readiness are at least partially 
independent of the BMI. This fact seems to confirm, 
especially in light of the evidence gathered from the 
general population, the importance of fibrinogen. The 
risk of cardiovascular and thromboembolic events can 
still be elevated despite successful surgical treatment.
Our study also analysed the role of D-dimer levels 
as a marker of coagulation-fibrinolysis system activa-
tion. D-dimers are final products of plasmin-mediated 
degradation of fibrin found within a thrombus and 
stabilised by cross-links between fibrin chains. Plasma 
D-dimer levels are a marker of increased activity of the 
coagulation system and the secondary fibrinolysis [27]. 
Therefore, increased plasma D-dimer levels indirectly 
correlate with increased generation of thrombin, which 
catalyses the conversion of fibrinogen to fibrin in blood 
vessels. This fact is used in the diagnostics of VTE. It 
is a relatively common practice to exclude deep vein 
thrombosis and pulmonary embolism on the basis of 
D-dimer levels below 0.5 µg/mL. High serum D-dimer 
levels are a compelling indication for further diagnostic 
test for VTE. Some authors indicate that D-dimer levels 
correlate with future development of deep vein throm-
bosis [27, 28]. At this point, it is important to consider 
other conditions that may lead to elevated D-dimer 
levels, such as chronic inflammation, malignancies, 
injuries, and pregnancy [27, 29]. The key advantages of 
a D-dimer test are its simplicity, rapidity, and low cost; 
while its key disadvantage is its low specificity in the 
clinical conditions mentioned above [27, 28].
The effect of glucocorticoids (GC) on D-dimer levels 
has been already reported. Brotman et al. demonstrated 
an increase in D-dimer following short-term treatment 
with dexamethasone in healthy volunteers [30]. 
Our prospective study showed D-dimer levels in 
patients with CD to be significantly higher than those 
in a sex- and age-matched control group. However, the 
available literature on the subject is scant. A prospec-
tive study by Manetti et al. also demonstrated elevated 
D-dimer levels in the group of patients with hypercor-
tisolism in comparison to those in healthy individuals. 
D-dimers were not separately analysed or discussed in 
this work, and the study group comprised both patients 
with CD and those with Cushing’s syndrome caused 
by cortisol-producing adrenal tumours [9]. Conversely, 
a study by Fatti et al. in a small heterogeneous patient 
population with Cushing’s syndrome of various origin 
showed no significant difference between D-dimer 
levels in the CD group and the healthy control [13]. 
A retrospective uncontrolled study by Fukuoka 
et al. in patients with CD, adrenal adenomas, ectopic 
ACTH secretion demonstrated a correlation between D-
dimer levels of ≥ 2.6 µg/dL and a high risk of deep vein 
thrombosis in patients with hypercortisolaemia. This 
value is lower than the D-dimer level associated with 
elevated risk of deep vein thrombosis in the general 
Japanese population. It was explained as a possible ef-
fect of plasminogen activation inhibitor 1 (PAI-1), whose 
concentration in hypercortisolaemia may be higher, 
leading to inhibition of fibrinolysis and slightly lower 
generation of D-dimers in Cushing`s syndrome [12]. 
Moreover, the study by Fukuoka et al. showed 
a positive correlation between plasma D-dimer levels/ 
/serum cortisol levels both in the morning and late eve-
ning. The authors observed also a correlation between 
higher cortisol levels following a low-dose dexametha-
sone suppression test (LDDST) and higher plasma 
D-dimer levels [12]. Our study did not confirm the cor-
relation between serum cortisol or urinary free cortisol 
and D-dimer levels. Admittedly, we did not routinely 
conduct the LDDST (4 × 0.5 mg dexamethasone for two 
days) in favour of an overnight 1-mg dexamethasone 
suppression test (ODST). There was also no observable 
association between post-ODST serum cortisol and 
plasma D-dimer levels. The findings yielded by our 
version of the dexamethasone suppression test are not 
consistent with Fukuoka’s et al. conclusion (the cortisol 
secretion autonomy having a more pronounced effect 
on D-dimer levels and thrombus formation than abso-
lute serum cortisol levels). Such a bold conclusion seems 
also to be contradicted by the commonly observed 
very high variability of serum cortisol levels both in 
normal conditions and in dynamic testing, especially 
in a highly heterogeneous group of patients with Cush-
ing’s syndrome of various aetiologies, which affects the 
level of cortisol suppression in LDDST. Moreover, apart 
from serum cortisol levels, the glucocorticoid receptor 
density also supposedly affects the biological effects of 
cortisol (including coagulation and fibrinolysis), and it 
would only be the combination of these two factors that 
would determine that biological effect.
Our study demonstrated a positive correlation be-
tween D-dimer levels and both patient age and hsCRP 
levels in patients with CD. This is consistent with earlier 
reports on the correlation of age and inflammation 
severity on one hand and D-dimer levels on the other, 
as demonstrated in non-CD populations [25, 27, 31].
Another important finding of our study was that 
patients with early remission of hypercortisolaemia did 
not show a decrease in D-dimer levels at three or six 
291
Endokrynologia Polska 2016; 67 (3)
PR
A
C
E 
O
RY
G
IN
A
LN
E
months following a successful transsphenoidal resec-
tion of a corticotroph pituitary tumour. In fact, three 
months after surgery serum D-dimer levels were found 
to be higher than in the preoperative period, while six 
months after surgery they returned to preoperative 
levels. Additionally, both at three and six months after 
surgery, D-dimer levels in the remission group were 
significantly higher compared to the control group. 
Unfortunately, there are few well-designed prospective 
studies on this subject. Persistently elevated plasma 
D-dimer levels following surgical treatment in a het-
erogeneous group of patients with Cushing’s syndrome 
were demonstrated by Manetti et al.; however, the 
authors did not discuss D-dimers specifically [9]. This 
finding may suggest a state of thrombotic readiness 
and secondary activation of fibrinolysis (as evidenced 
by D-dimer levels) persisting for six months in the re-
mission group, despite serum cortisol and urinary free 
cortisol being lowered, even down to subnormal levels. 
This fact seems to indicate a need for closer patient 
monitoring for signs of VTE or pulmonary embolism at 
postoperative follow-up visits. In some cases, imaging 
studies, such as lower-extremity deep vein ultrasonog-
raphy, may be considered. We would like to emphasise 
that there are no specific guidelines for diagnostic and 
therapeutic management of CD patients, and the for-
mulation of such guidelines would require studies in 
a larger patient group to include both thromboembolic 
risk factor evaluation and imaging studies.
Conclusions
In conclusion, our study demonstrated persistently 
higher levels of both fibrinogen and D-dimers for a 
period of at least six months following an initially 
successful surgical treatment for CD, compared with 
controls. This seems to indicate a need for a closer 
postoperative follow-up for signs of cardiovascular 
and thromboembolic complications in patients with 
early CD remission. 
A concomitant comprehensive approach to other 
established modifiable cardiovascular risk factors seems 
to be also advisable, in order to improve prognosis. 
However, the formulation of guidelines for extended 
anti-thrombotic prevention even after a successful pi-
tuitary corticotroph tumour resection requires larger, 
multicentre, prospective clinical studies involving im-
aging diagnostics. This may allow us to determine the 
actual rates of VTE, and possibly to establish the CD-
specific cut-off point for D-dimer levels and/or other 
haemostasis parameters associated with a higher risk 
of deep vein thrombosis and/or pulmonary embolism.
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